art for cervical cancer: dosimetry and technical...

38
ART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray, Ph.D. Radiation Therapy Physics Princess Margaret Cancer Centre/Techna/Ontario Cancer Institute Professor Departments of Radiation Oncology and Medical Biophysics University of Toronto

Upload: others

Post on 16-Oct-2020

3 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

ART for Cervical Cancer:

Dosimetry and Technical Aspects

D.A. Jaffray, Ph.D.

Radiation Therapy Physics

Princess Margaret Cancer Centre/Techna/Ontario Cancer Institute

Professor

Departments of Radiation Oncology and Medical Biophysics

University of Toronto

Page 2: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

AAPM’13

Acknowledgements Princess Margaret Cancer Centre

J. Stewart, K.K. Brock, Y.-B. Cho, A. Fyles, M. Milosevic, K. Lim,

H. Alasti, M. Islam, S. Foxcroft, R. Dahdal, A. Simeneov,

M. Carlone, T. Stanescu, S. Breen, M. Gospodarowicz

RaySearch Laboratories – A. Lundin, H. Rehbinder, J. Lof

IMRIS - M. Dahan, J. Winters, D. Graves, B. Guyot, L. Petropoulus

Varian - M. Sweitzer

Funding: Canadian Foundation for Innovation, CIHR, OICR

Fidani Chair in Radiation Physics

Page 3: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Background – EBRT+CT

Increased progression-free survival.

Reduced local and distant recurrence.

Acute toxicity increased.

Late toxicities?

Green, et al., Cochrane Review 2005:CD002225

Kirwan, et al., Radiotherapy & Oncology 2003;68:217-226

+

Page 4: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Background - IMRT

Four-Field Box

Rectum

Bladder

Nodal CTV

Tumour CTV

IMRT

Page 5: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

MR-based Motion Assessment in Ca Cervix

• Inter- and Intrafractional Movement of the Uterus and

Cervix in Patients with Cervix Cancer Receiving

Radiotherapy: An MRI-Based Point-of-Interest (POI)

Analysis

• Patients treated with radical chemo-radiotherapy imaged

with serial Cine-MRI scans

Page 6: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Background – Morphological Changes over Tx

Pre-Tx 8 Gy 20 Gy

28 Gy 38 Gy 48 Gy

Page 7: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Combined

Motion

and

Response

7 July

21 July

14 July

5 Aug

30 Minute

Acquisition

Cycle

Page 8: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

AAPM’13

Challenges in IMRT for Cervix Cancer

Target Identification

• MR vs CT

• Nodal targets

• Online image quality

Organ motion

• Influence of

– Bladder filling

– Rectal filling

– Normal uterus position

Page 9: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Week 1 Week 2 Week 3 Week 4 Week 5

Background – Interfraction Motion

ORBIT Workstation

Planning

Rectum-

Sigmoid

Tumour

Cervix Uterus

Bladder

Background – Interfraction Motion

Page 10: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Week 1

Background – Interfraction Motion

ORBIT Workstation

Rectum-

Sigmoid

Tumour

Cervix Uterus

Bladder

Background – Interfraction Motion

Page 11: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Week 2

Background – Interfraction Motion

ORBIT Workstation

Rectum-

Sigmoid

Tumour

Cervix Uterus

Bladder

Background – Interfraction Motion

Page 12: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Week 3

Background – Interfraction Motion

ORBIT Workstation

Rectum-

Sigmoid

Tumour

Cervix Uterus

Bladder

Background – Interfraction Motion

Page 13: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Week 4

Background – Interfraction Motion

ORBIT Workstation

Rectum-

Sigmoid

Tumour

Cervix Uterus

Bladder

Background – Interfraction Motion

Page 14: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Week 5

Background – Interfraction Motion

ORBIT Workstation

Rectum-

Sigmoid

Tumour

Cervix Uterus

Bladder

Background – Interfraction Motion

Page 15: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Aim

Use weekly imaging feedback to dosimetrically and volumetrically monitor treatment progress and adapt to ensure clinical goals are met.

Plan A

MRI

MRI

Plan A

Plan B

MRI Plan B

MRI Plan B

Page 16: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

0 5 10 15 20 25 0

10

20

30

40

50

To

tal Ta

rget

Dose

(G

y)

Fraction

Aim

Replan

Weekly

Imaging

Use weekly imaging feedback to dosimetrically and volumetrically monitor treatment progress and adapt to ensure clinical goals are met.

Page 17: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Aim

Replan to further

OAR dose sparing

Weekly

Imaging

0 5 10 15 20 25 0%

100%

Ta

rget

Volu

me

Fraction

Use weekly imaging feedback to dosimetrically and volumetrically monitor treatment progress and adapt to ensure clinical goals are met.

Page 18: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Methods

• 33 patients with stage IB-IVA cervix cancer

• Target volumes (GTV and CTV) and OARs (rectum, sigmoid, bladder, and bowel) contoured on fused MR-CT baseline image and subsequent weekly MR scans

• Primary CTV (pCTV) defined as union of:

– GTV

– Cervix

– Parametria

– 2 cm of uterus superior to GTV

– 2 cm of upper vagina inferior to GTV

Rectum

GTV Bowel Sigmoid

Bladder CTV

Page 19: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Methods – Deformable Registration

Planning (pre-treatment)

Week 1 Week 2 Week 3

Week 4 Week 5

Brock, et al., Medical Physics 2005;32:1647-1659.

Page 20: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

+

Methods – Dose Accumulation / ORBIT

Planned Dose

Accumulated Dose

Apply planned dose

at each fraction

Deform each fraction

to planning geometry

Accumulate across

all fractions

Page 21: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Accumulated (where the dose was actually delivered)

Planning (where we planned the dose to go)

Methods - ORBIT

Difference Did we miss the target?

Were OARs compromised?

Cold spot in tumour Higher sigmoid dose

than planned

Page 22: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Planning Scenarios

Planning Accumulate

IMRT w/ 3mm PTV margin Criteria: • D98% GTV > 50 Gy • D98% CTV > 49 Gy • D98% PTV > 47.5 Gy

25 Fractions

IMRT Plan Optimization Function

Initiate replan if weekly dose accumulation

triggers one of the following:

1) D98% GTV < 49 Gy or

D98% CTV < 47.5 Gy

2) CTV volume drops 100 cm3

Dose triggers

Volume trigger

Planned 1 No Replan 2 Assess Weekly 3

Page 23: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Example Patient #1

Week 2 – without

Re-plan

Planned

Page 24: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Automated Weekly Replan (Week 2)

Automated Weekly Replan (Week 2)

No Replan (Week 2)

No Replan (Week 2)

Results – Example of Improved Target Coverage

GTV CTV

Planned

Delivered

Planned No Replan Weekly Replan

GTV 50.1 47.4 50.2

CTV 49.1 46.5 49.1

Dose to 98% Volume (Gy)

Bladder

Page 25: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

5.6 cm

Example Patient #2

Page 26: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Example Patient #2

GTV

CTV

Planned Week 4

Page 27: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Example Patient #2

Week 4 / No Replan Week 4 / Replan to reduce dose to OARs

Page 28: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Planned No Replan Assess Weekly45

46

47

48

49

50

51

Do

se

to

98

% V

olu

me

(G

y)

100%

98%

95%

Planned No Replan Assess Weekly45

46

47

48

49

50

51

Do

se

to

98

% V

olu

me

(G

y)

100%

98%

95%

Results – Target Coverage

GTV CTV

8

(24%)

2

(6%)

Page 29: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Results – Replanning Workload vs Week

1 2 3 4 50

2

4

6

8

10

12

14

Num

ber

of

Rep

lans

MRI / Week

Target dosimetry (24 replans)

CTV regression (12 replans)

Both (1 replan)

n = 33 n = 14

Page 30: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Results – Distribution of Triggered Plans

Page 31: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Limitations of the Study

• MRI scans obtained each week expanded to represent

each fraction

– For example, scan 1 at fraction 1 assumed to be

representative of fractions 1-5

• Perfect bone-bone matching assumed at each fraction

• Deformable registration algorithm MORFEUS

currently undergoing accuracy validation for cervix

(validated in lung, prostate and liver)

Page 32: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Summary of Adaptive Planning Study

• A 3 mm PTV margin for cervix cancer is valid

for a subset of patient (76%), but we don’t

know who they are until we have imaged them

for ~2 weeks.

• Opportunity to reduce dose to normal tissues

with this strategy while assuring target

coverage.

• Dosimetric triggers of target coverage do not

maximize the normal tissue dose reduction.

Page 33: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

The Princess MRgRT Facility

Tri-use Facility based on a single 1.5T magnet and state-of-the-art delivery

Page 34: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

MRgRT Pelvis Configuration

Page 35: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Prostate

MRgRT Pelvis Coil: Volunteer Images

1.5 T, T2 weighted images of two volunteers.

Page 36: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

MRgRT Pelvis Coil: Volunteer Images

Prostate

1.5 T, T2 weighted images of two volunteers.

Page 37: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

MRgRT External Beam Workflow

IGRT-guided pre-localization

of MR Imaging FOV

Confirmation of delivery

viability

Reference CBCT for MR-

guidance

Robotic control of MR, table

and Shielding System

Linear motion of magnet

over patient.

RT present for movement.

Pre-stored MR configuration

from MR-simulation Stage

Critical time specification

(<90s) from end of imaging

to beam-on.

Image processing (distortion

correction, calibration) and

planning (adaptation).

Generation of couch or

machine adjustment.

*MR can begin image within 5s of stopping.

Page 38: ART for Cervical Cancer: Dosimetry and Technical Aspectsamos3.aapm.org/abstracts/pdf/77-22590-312436-91597.pdfART for Cervical Cancer: Dosimetry and Technical Aspects D.A. Jaffray,

Summary

• Developed an experience in the use of MR for adaptive RT of the cervix using retrospective analysis.

• Anticipate significant advantages wrt normal tissue dose reduction with reasonable workload using weekly MR imaging.

• Building a system that will enable state-of-the-art MR imaging for adaptation.

• Exciting prospect for adaptive workflows that will assure coverage and reduce normal tissue dose.